Activated clotting time (ACT)

Methods in Molecular Biology

Volumn 992, Issue , 2013, Pages 155-167

  Horton, Stephen ^a   Augustin, Simon ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Activated clotting time; Coagulation monitoring; Hemochron; Hemotec; MAX ACT; Whole blood coagulation time

Indexed keywords

APROTININ; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; GLASS; INFUSORIAL EARTH; KAOLIN; PHOSPHOLIPID;

ACTIVATED CLOTTING TIME; ANALYZER; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; CATHETERIZATION; FIBRINOGEN BLOOD LEVEL; HEMODILUTION; HEMOSTASIS; HUMAN; HYPOTHERMIA; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 84877138192     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-339-8_12     Document Type: Article

References (31)

1. Royston D (1996) Preventing the in fl ammatory response to open-heart surgery: The role of Aprotinin and other protease inhibitors. Int J Cardiol 53(suppl):S11-S37
2. Despotis GJ, Gravlee G, Filos K, Levy J (1999) Anticoagulation monitoring during cardiac surgery. Anesthesiology 91:1122-1151
3. Ammar T, Scudder LE, Coller BS (1997) In vitro effects of platelet Glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 95:614-617
4. Despotis GJ, Summer fi eld AL, Joist JH et al (1994) Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentrations in patients having cardiac operations. Thorac Cardiovasc Surg 108: 1076-1082
5. Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA (2005) Anticoagulation monitoring part 2: Unfractionated heparin and lowmolecular-weight heparin. Ann Pharmacother 39(7-8):1275-1285
6. Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai JB, Despotis GJ, Hunt BL (2004) Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 92:178-186
7. Hattersley PG (1966) Activated clotting time of whole blood. JAMA 196:436-440
8. Graves DF, Chernin JM, Kurusz M, Zwischenberger JB (1996) Anticoagulation practices during neonatal extracorporeal membrane oxygenation: Survey results. Perfusion 11:461-466
9. McManus ML, Kevy SV, Bower LK, Hickey PR (1995) Coagulation factor deficiencies during initiation of extracorporeal membrane oxygenation. J Pediatr 126:900-904
10. MIMS on-line (2003) Copyright MIMS Australia Pt. Ltd. http://www.mims.com.au
11. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH (1990) Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:788-797
12. Khan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Sellke FW (2005) Aprotinin inhibits platelet aggregation and thrombosis. Ann Thorac Surg 79:1545-1550
13. Wang JS, Lin CY, Hung WT, Karp RB (1992) Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with Aprotinin. Anesthesiology 77(6):1080-1084
14. Dietrich W, Jochum M (1995) Effect of celite and kaolin on activated clotting time in the presence of Aprotinin: Activated clotting time is reduced by binding of Aprotinin to kaolin. J Thorac Cardiovasc Surg 109:177-186
15. Machin D, Devine P (2005) The effect of temperature and Aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra Corpor Technol 37(3):265-271
16. Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M (2004) A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 56(6):1221-1228
17. Kase PB, Dearing JP (1985) Factors affecting activated clotting time. J Extra Corpor Technol 17(1):27-30
18. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H (1995) Heparin and Antithrombin III levels during cardiopulmonary bypass: Correlation with subclinical plasma coagulation. Ann Thorac Surg 58:799-805
19. Kadakia RA, Baimeedi SR, Ferguson JJ (2004) Low-molecular-weight heparins in the cardiac catheterization laboratory. Tex Heart Inst J 31(1):72-83
20. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF (2003) The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 41:394-403
21. Operation manual. MAX-ACT activated clotting time test. Helena Laboratories point of care. Beaumont, Texas, USA
22. Operation manual. Hemotec ACT II activated clotting time test. Medtronic. Minneapolis, MN, USA
23. Instrument operator manual. Hemochron Jr.signature whole blood microcoagulation system - International Technidyne Corporation. Edison, NJ, USA
24. Instrument operator manual, HEMOCHRON ® response activated clotting time test -International Technidyne Corporation. Edison, NJ, USA
25. Koster A, Despotis G, Gruendel M, Fischer T, Praus M, Kuppe H, Levy J (2002) The plasma supplemented modi fi ed activated clotting time for monitoring of heparinization during cardiopulmonary bypass: A pilot investigation. Anesth Analg 95:26-30
26. Gil W (2001) In fl ammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation. Perfusion 16:27-35
27. Horton SB, Butt WW, Mullaly RJ, Thuys CA, O'Connor EB, Byron K, Cochrane AD, Brizard CP, Karl TR (1999) IL-6 and IL-8 levels following cardiopulmonary bypass are not affected by surface coating. Ann Thorac Surg 68:1751-1755
28. Bosch YPJ, Ganushchak YM, de Jong DS (2006) Comparison of ACT point-of-care measurements: Repeatability and agreement. Perfusion 21:27-31
29. El Rouby S, Cohen M, Gonzales A, Hoppensteadt D, Lee T, Zucker ML, Khalid K, LaDuca FM, Fareed J (2006) The use of Hemochron ® Jr. Hemonox™ point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures. J Thromb Thrombolysis 21: 137-145
30. Yamada T, Katori N, Tanaka K, Takeda J (2007) Impact of Sonoclot hemostasis analysis after cardiopulmonary bypass on postoperative hemorrhage in cardiac surgery. J Anesth 21: 148-152
31. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA (1999) Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 88:312-319